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AbsTRACT
Atrial fibrillation (AF) is characterised by an increased 
risk of pathological thrombus formation due to a 
disruption of physiological haemostatic mechanisms 
that are better understood by reference to Virchow’s 
triad of ’abnormal blood constituents’, ’vessel wall 
abnormalities’ and ’abnormal blood flow’. First, there 
is increased activation of the coagulation cascade, 
platelet reactivity and impaired fibrinolysis as a result of 
AF per se, and these processes are amplified with pre- 
existing comorbidities. Several prothrombotic biomarkers 
including platelet factor 4, von Willebrand factor, 
fibrinogen, β-thromboglobulin and D- dimer have been 
implicated in this process. Second, structural changes 
such as atrial fibrosis and endothelial dysfunction are 
linked to the development of AF which promote further 
atrial remodelling, thereby providing a suitable platform 
for clot formation and subsequent embolisation. Third, 
these factors are compounded by the presence of 
reduced blood flow secondary to dilatation of cardiac 
chambers and loss of atrial systole which have been 
confirmed using various imaging techniques. Overall, an 
improved understanding of the various factors involved 
in thrombus formation will allow better clinical risk 
stratification and targeted therapies in AF.
InTRoduCTIon
Disruption of normal haemostatic mechanisms 
can lead to pathological thrombus formation. The 
mechanism by which this occurs in atrial fibrillation 
(AF) is complex and multifactorial. Over a century 
ago, Rudolf Virchow described three main factors 
involved in thrombus formation as follows: (1) 
abnormal blood constituents; (2) vessel wall abnor-
malities and (3) abnormal blood flow.1 This descrip-
tion, known as Virchow’s triad, has withstood the 
test of time and may be useful to better understand 
the prothrombotic state in AF (figure 1).
Abnormal blood constituents (hypercoagulability)
Hypercoagulability is principally related to either 
activation of the coagulation cascade, increased 
platelet reactivity or impaired fibrinolysis. Each of 
these factors have been implicated in AF (table 1). In 
general, the most significant cause for a prothrom-
botic state relates to activation of the coagulation 
cascade for which thrombin is a necessary compo-
nent. Therefore, the rate of thrombin genera-
tion may reflect the degree of thrombogenicity, 
and this can be derived from levels of thrombin- 
antithrombin complex (TAT) and prothrombin 
fragment F1 +2 (F1 +2). Other markers of hyper-
coagulability include von Willebrand factor (vWf) 
and fibrinogen, which are both directly involved in 
clot formation. In addition, D- dimer may be used as 
a marker of fibrin turnover, and platelet activation 
may be inferred from levels of P- selectin, platelet 
factor 4 (PF-4) and β-thromboglobulin. Raised 
tissue plasminogen activator (tPA) levels typically 
results from secondary fibrinolysis which occurs 
due to increased clot formation. However, in the 
presence of raised plasminogen activator inhib-
itor-1 (PAI-1), most tPA are bounded and remain 
inactive. Hence, high concentrations of both indices 
may also suggest impaired fibrinolysis.
Elevated levels of F1 +2 in patients with AF 
compared with sinus rhythm (SR) have previously 
been demonstrated.2 3 Furthermore, patients with 
chronic AF have increased coagulation factors 
(factor VIII:C, vWf and fibrinogen), platelet activa-
tion (PF-4 and β-thromboglobulin) and secondary 
fibrinolysis (D- dimer and spontaneous amido-
lytic activity).4 5 The introduction of warfarin 
normalised circulating D- dimer levels, suggesting 
that warfarin was effective in preventing excessive 
fibrin turnover. However, the use of warfarin had 
an apparent lack of effect on levels of fibrinogen 
and vWf, reinforcing the fact that warfarin does 
not influence the underlying pathological process 
in AF.5 Importantly, the findings suggest that both 
these biomarkers may be used as a risk indicator for 
hypercoagulability even in anticoagulated patients 
with AF. Further clinical studies have confirmed 
that increased levels of vWF is associated with 
greater thromboembolic risk.6 7
Atrial fibrillation vs comorbidities
Many observational studies investigating the 
prothrombotic state in AF are confounded by group 
differences in baseline characteristics which are 
known to influence haemostasis. Therefore, despite 
well- defined increases in various prothrombotic 
indices among patients with AF, it remains unclear 
whether these are due to AF itself or pre- existing 
comorbidities.
A study evaluating patients with AF and no 
other major thromboembolic risk factors (‘lone’ 
AF) found that these patients had higher levels 
of PF-4, β-thromboglobulin, fibrinogen, vWf, 
D- dimer, tPA and PAI compared with age- matched 
and sex- matched healthy controls.8 Lone AF has 
also been associated with increased levels of P- se-
lectin.9 Furthermore, Makowski et al proved that 
cardioversion of patients with lone AF resulted in 
a reduction of platelet reactivity after 4 weeks.10 
These studies suggest that the presence of AF alone 
is sufficient to promote a prothrombotic state.
In contrast, the Framingham Offspring Study 
found that higher levels of fibrinogen, vWf and tPA 
in patients with AF were the result of other cardio-
vascular risk factors.11 Additionally, while increased 
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Figure 1 Effects of atrial fibrillation on the various elements of 
Virchow’s triad.
Table 1 Effects of AF on hypercoagulability
study study population n Relevant findings
Akar et al17 Paroxysmal AF undergoing catheter ablation 22 AF lasting up to 15 min was independently associated with increased local cardiac P- selectin, TAT complex and 
prothrombin fragment, and decreased nitric oxide production with no change in inflammatory markers.
Choudhury et al12 AF 221 Increased platelet adhesion in AF could be accounted for by pre- existing comorbidities.
Antithrombotic use was associated with normalisation of platelet adhesion in AF.
Feng et al11 Community- based cohort 3577 Increased fibrinogen, vWf and tPA antigen in AF were due to concomitant cardiovascular risk factors.
Fu et al9 Idiopathic AF 90 Increased soluble P- selectin and fibrinogen.
Gustafsson et al4 Non- valvular AF with and without previous stroke 100 Increased vWf, factor VIII:C, fibrinogen, D- dimer, β-thromboglobulin, PF-4 and fibrinogen/antithrombin ratio.
Krishnamoorthy et al6 AF, attending outpatient clinics 423 Higher vWF and soluble E- selectin levels in AF were associated with greater risk of composite end point and 
ischaemic stroke.
Lim et al18 AF undergoing catheter ablation 87 Increased P- selectin and TAT complex in the left atrium compared with femoral vein.
Lip et al5 Chronic AF with and without anticoagulation 87 Increased fibrinogen, vWf and D- dimer.
Warfarin use was associated with normalisation of D- dimer levels in chronic AF.
Lip et al14 AF with and without anticoagulation undergoing 
cardioversion
19 Maintenance of SR following cardioversion in non- anticoagulated AF was associated with decreased D- dimer but 
no change in fibrinogen.
Maintenance of SR following cardioversion in anticoagulated AF was associated with no change in D- dimer or 
fibrinogen.
Makowski et al10 Lone AF undergoing cardioversion 36 Maintenance of SR was associated with decreased platelet reactivity as measured by mean fluorescence intensity 
of CD42b and CD62 on thrombin- stimulated platelets.
Marin et al16 First onset acute non- anticoagulated AF in whom SR 
was restored within 48 hours
96 AF lasting <48 hours was associated with increased soluble thrombomodulin, vWf and D- dimer.
Successful cardioversion was not associated with changes in soluble thrombomodulin, vWf, D- dimer and 
echocardiographic indices.
Mondillo et al8 Lone permanent non- rheumatic AF 80 Increased PF-4, β-thromboglobulin, fibrinogen, vWf, D- dimer, tPA and PAI.
Pinto et al7 Chronic AF 373 Higher vWF levels in chronic AF were associated with greater ischaemic stroke risk.
Topcuoglu et al3 Lone AF with acute MCA ischaemic stroke 131 Increased F1 +2.
Cardioembolic stroke secondary to AF or other causes was associated with increased TAT compared with those with 
an atherosclerotic cause.
Turgot et al2 Non- valvular AF with acute ischaemic stroke 75 Increased F1 +2 and reduced fibrinogen.
Yip et al13 Chronic non- valvular AF 82 Increased expression of CD62p but only in the presence of concomitant diabetes mellitus.
AF, atrial fibrillation; F1 +2, prothrombin fragment F1 +2; MCA, middle cerebral artery; PAI, plasminogen activator inhibitor; PF-4, platelet factor 4; SR, sinus rhythm; TAT, thrombin- antithrombin complex; tPA, tissue 
plasminogen activator; vWf, von Willebrand factor.
platelet activation is evident in AF, these platelet indices may 
be accounted for by pre- existing comorbidities (eg, vascular 
disease).12 A separate study reported no differences in platelet 
activation among patients with chronic AF compared with 
healthy controls, unless they suffered from concomitant diabetes 
mellitus.13 However, over half the patients with AF were treated 
with warfarin which could have attenuated any negative effects 
of the arrhythmia.
Overall, it is likely that both AF and its associated comorbid-
ities may contribute to a prothrombotic state. This is supported 
by a previous small study which suggested that successful cardio-
version was associated with a significant reduction in selected 
prothrombotic biomarkers such as D- dimer, but not fibrin-
ogen.14 However, the effects may only be realised over time as 
the immediate period following cardioversion is often linked to 
an increased risk of thromboembolic events due to ‘atrial stun-
ning’ induced by conversion of AF to SR.15
Threshold of AF duration
Having established the contribution of AF to a prothrombotic 
state, it is important to determine whether there is an arrhythmic 
threshold required for this to occur. There is limited research in 
this particular area.
New- onset acute AF of <48 hours was found to generate 
increased thrombogenesis at least up to 30 days later, despite no 
further AF recurrence.16 Another case- controlled study demon-
strated that 15 min of AF was sufficient to increase central 
platelet activation (P- selectin) and thrombin generation (TAT 
and F1 +2).17 Akar et al found that this happened indepen-
dent of changes in inflammatory markers (C reactive protein 
and interleukin-6), suggesting that there are other mechanisms 
involved. Overall, thrombogenesis may be impacted by the dura-
tion of AF per se, although this remains a controversial topic.
Central versus peripheral coagulability
Most studies in AF have focused on assessment of peripheral 
blood samples. However, as the majority of thrombus forma-
tion occurs in the left atrium (LA), specifically the left atrial 
appendage (LAA), these peripheral samples may not provide an 
accurate reflection of the prothrombotic state in AF.
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Figure 2 Interaction between vascular injury in atrial fibrillation 
and the initiation of clot formation in the presence of increased 
prothrombotic elements Figures are generated using BioRender.
Table 2 Effects of AF on structural changes
study study population n Relevant findings
Boldt et al26 AF 118 Increased collagen I and III.
Climent et al30 Persistent AF undergoing DCCV 86 Reduced MMP-1.
Maintenance of SR following cardioversion was not associated with a change in MMP-1 and TIMP-
1.
Goette et al38 Persistent AF undergoing DCCV 60 Increased endothelial dysfunction as measured by ADMA.
Lim et al18 AF undergoing catheter ablation 87 Increased ADMA.
Maintenance of SR following cardioversion was associated with normalisation of ADMA.
Marin et al29 Chronic non- anticoagulated AF 48 Reduced levels of MMP-1, and increased TIMP-1 and ratio of TIMP-1 to MMP-1 were due to the 
combined effects of AF and concomitant risk factors.
There was an independent relationship between the MMP/TIMP system and prothrombotic state as 
assessed by F1 +2.
Masawa et al25 Cerebral embolism with and without AF 
(autopsy)
31 Changes in the left atrial endocardium including a granular and wrinkled appearance associated 
with oedematous and fibrous thickening; mural thrombi and endothelial denudation and 
thrombotic aggregations.
Nakamura et 
al41
Cardiogenic thromboembolism with non- 
valvular AF
7 Increased endothelial injury as assessed by over- expression of vWf.
Shirani and 
Alaeddini et al24
Chronic AF (autopsy) 46 Increased LAA volume, luminal surface area of the bisected LAA and endocardial thickening with 
fibrous and elastic tissue and reduced transected pectinate muscles.
F1 +2, prothrombin fragment F1 +2; ADMA, asymmetric dimethylarginine; AF, atrial fibrillation; DCCV, direct current cardioversion; LAA, left atrial appendage; MMP-1, matrix 
metalloproteinase-1; SR, sinus rhythm; TIMP-1, tissue inhibitor of matrix metalloproteinase-1; vWf, von Willebrand factor.
Indeed, a relatively short duration of AF has been associated 
with increased platelet activation (P- selectin) within the coro-
nary sinus but not in the femoral vein.17 In addition, periph-
eral levels of P- selectin were similar between patients with lone 
AF, patients with AF and multiple comorbidities and controls, 
despite being markedly raised in the LA of patients from the two 
former groups.18 Elevated levels of biomarkers relating to coag-
ulation, fibrinolysis and fibrosis have also been shown in the LA 
compared with peripheral samples of patients with AF.19
Overall, central changes in thrombogenesis may precede those 
in the peripheral system, which may require a longer duration of 
AF to become manifest. Therefore, evaluation of prothrombotic 
biomarkers in blood samples from the LA may be more sensitive 
for detection of the hypercoagulable state in AF.
Role of platelet activation
Vascular injury in AF (described below) initiates primary haemo-
stasis in the presence of increased prothrombotic elements 
resulting in vascular spasm, and platelet adhesion, activation 
and aggregation (figure 2). Rapid vascular spasm involving 
circular and occasionally longitudinal smooth muscle cells act 
to reduce blood flow to the area of injury while allowing other 
haemostatic mechanisms to operate. Despite much evidence to 
support the role of platelet activation in the prothrombotic state 
in AF,4 8–10 17 there are conflicting results reported elsewhere.
In the study by Choudhary et al, there was no relation 
between platelet adhesion and stroke risk in AF, based on the 
CHADS2 stroke risk scoring system.
12 A substudy from the 
Stroke Prevention in Atrial Fibrillation III trial also found that 
increased platelet activation, measured by β-thromboglob-
ulin levels, was not associated with thromboembolism in AF.20 
Furthermore, no differences in biomarkers of platelet activity 
were demonstrated following acute cardioembolic stroke in 
patients with AF compared with age- matched and sex- matched 
healthy controls.21 However, these studies were performed on 
peripheral blood samples and may not be reflective of condi-
tions within the LA. Nonetheless, it is perhaps pathophysiologi-
cally unsurprising since the clinical use of antiplatelets for stroke 
prevention in AF has been shown to be ineffective20 and inferior 
to oral anticoagulation therapy.22
Vessel wall abnormalities (eg, endothelial injury, structural 
changes)
Certain structural changes in the atria may predispose to the 
development of AF that subsequently promotes further remod-
elling.23 Overall, these alterations contribute to the prothrom-
botic tendencies observed in AF through a variety of mechanisms 
(table 2). Histological examination of the LAA found that AF 
was associated with a significant increase in LAA volume and 
luminal surface area; reduction in pectinate muscle volume and 
surface area and marked endocardial thickening with fibrous 
and elastic tissue.24 Combined with loss of atrial transport factor 
(‘atrial kick’), these changes may promote abnormal blood 
stasis (discussed below). The exact relevance of a reduction in 
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Table 3 Effects of AF on abnormal blood stasis
Author (ref) study population n Relevant findings
Ammash et al46 Non- valvular AF 514 The presence and intensity of spontaneous echo contrast in AF was directly related with levels of vWf antigen and activity 
which were independent predictors of LAA thrombus after adjustment for CHADS2 score.
Black et al44 Non- valvular AF 
undergoing TOE
135 Spontaneous echo contrast in non- valvular AF was independently associated with increased haemotocrit, fibrinogen and LA 
dimension.
Markl et al43 AF 75 Complex haemodynamic changes in the LA and LAA including reduced peak and mean velocities, and increased flow stasis.
Vincelj et al42 Patients 
undergoing TOE
290 AF was associated with the presence of spontaneous contrast echo.
Wysokinski et al47 Non- valvular AF 151 Severe spontaneous contrast echo in AF was associated with increased soluble P- selectin.
AF, atrial fibrillation; LA, left atrial; LAA, left atrial appendage; TOE, trans- oesophageal echocardiography; vWf, von Willebrand factor.
pectinate muscles in AF remains unclear, although it could be 
speculated that this may encourage thrombus dislodgement.
Masawa et al found that morphological changes of a ‘rough’ 
endocardium due to a granular and wrinkled appearance with 
oedematous and fibrous thickening was strongly associated 
with AF, as these changes were not apparent in those without 
the condition.25 Furthermore, the authors demonstrated that 
the incidence of a rough endocardium was almost universally 
correlated to the presence of mural thrombi on microscopic 
investigations. Using, scanning electron microscopy, AF was also 
linked to increased areas of endothelial denudation and throm-
botic aggregations in the LA.25 The structural changes that occur 
in AF appears to provide a platform for microscopic thrombi 
formation that heralds thromboembolic events.
Atrial fibrosis
Extracellular matrix (ECM) is an extensive network of macro-
molecules (such as collagen, enzymes and glycoproteins) that has 
an important role in providing physical and biochemical support 
to surrounding cells. It is one of the most important regulators 
in cellular and tissue function. However, excessive deposition of 
ECM leads to fibrosis. A previous study showed AF was associ-
ated with LA fibrosis through increased expression of collagen 
types I and III.26 This is relevant as LA fibrosis, assessed using late 
gadolinium enhancement MRI, has been independently linked 
to thrombus formation in the LAA.27 In addition, animal models 
using CREM- transgenic mice which exhibits key characteristics 
of persistent AF, demonstrate a propensity for development of 
the arrhythmia and thrombus formation.28
Although the correlation of AF and atrial fibrosis is well- 
established, the underlying mechanisms are poorly understood. 
Furthermore, it is unclear whether atrial fibrosis is a cause or 
consequence of AF. However, the process by which atrial fibrosis 
occurs is likely to involve matrix metalloproteinase (MMP) and 
tissue inhibitor of matrix metalloproteinase (TIMP). MMPs are 
involved in the breakdown of ECM while the actions of MMPs 
are inhibited by TIMP. Therefore, any resultant changes on 
either of these proteins may negatively impact matrix degrada-
tion and promote fibrosis.
Marín et al demonstrated lower levels of MMP-1 and higher 
levels of TIMP-1 among patients with AF compared with 
controls.29 However, the findings appeared to be driven by 
the combined effects of AF and other comorbidities. A major 
limitation of the study was the relatively short period from 
diagnosis of AF to enrolment. As a result, more marked abnor-
malities secondary to AF may not have had sufficient time to 
manifest. Nevertheless, a subsequent study by the same group 
found that despite lower levels of MMP-1 and comparable levels 
of TIMP-1 at baseline among patients with AF compared with 
healthy controls, maintenance of SR at 1 month following direct 
current cardioversion was not associated with any change in 
these variables compared with baseline.30 In contrast, a system-
atic review and meta- analysis of 33 studies found that AF was 
associated with no difference in levels of circulating MMP-1 
but elevated levels of atrial tissue MMP-1, circulating and atrial 
tissue MMP-2, and MMP-9, and reduced levels of circulating 
TIMP-2.31 However, many of the included studies were subject 
to significant publication bias rendering the associations between 
MMP-2 and MMP-9 in AF uncertain.
Overall, although it is difficult to elucidate the exact effects of 
AF with its respective comorbidities on the MMP/TIMP system, 
it does appear that the arrhythmia contributes to atrial fibrosis 
via different pathways. Furthermore, the hypercoagulable state 
during AF may promote profibrotic and pro- inflammatory 
responses.32
Role of MMP/TIMP system in coagulation
In vitro studies using human vein and rabbit aorta to demon-
strate that thrombin may contribute to the vascular response 
to injury by activation of latent MMP-2.33 In return, MMPs 
may participate in clot formation via the coagulation cascade 
and platelet activation. A study involving chimeric mice found 
that inactivation of the MMP-2 gene resulted in hyporeactive 
platelets and a defective thrombotic response.34 Furthermore, 
replacement of MMP-2 restored normal platelet and throm-
botic functions. Falcinelli et al demonstrated that vascular injury 
was associated with a significant increase in MMP-2 released by 
activated platelets that potentiated further platelet activation.35 
Interestingly, aspirin did not influence the expression of MMP-2 
despite suppression of serum thromboxane B2 and P- selectin.35 
The study by Marín et al further reinforces the link between the 
MMP/TIMP system and coagulation cascade.29
When considering this topic, it is important to recognise that 
there are various MMPs with potentially differing roles in clot 
formation. A systematic in vitro comparison of different MMPs 
under flow conditions demonstrated that inhibition of MMP-1 
or MMP-2 suppressed platelet activation, whereas inhibition of 
MMP-9 or MMP-14 stimulated these processes.36 Therefore, 
tight regulation of the MMP/TIMP system is necessary to main-
tain haemostasis and disruption of these physiological processes 
in AF may result in abnormal thrombus formation.
Endothelial dysfunction
In addition to the effects of endothelial dysfunction or injury 
as described above, there is a release of a variety of factors such 
as tissue factor, vWf and asymmetric dimethylarginine (ADMA) 
involved in clot formation. ADMA functions as an endogenous 
inhibitor of endothelial nitric oxide (NO) production and excess 
ADMA may contribute to endothelial dysfunction.37 A previous A
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study found that patients with AF had higher levels of ADMA 
compared with those in SR.38 Furthermore, the normalisation of 
ADMA levels were observed at 24 hours after successful DCCV, 
suggesting a direct influence from AF itself. Lim et al demon-
strated a stepwise increase in ADMA levels from controls to 
patients with lone AF to patients with AF and comorbidities.18
A study in porcine models demonstrated that AF was associ-
ated with marked reduction in endocardial NO synthase expres-
sion and a corresponding drop of NO levels that resulted in an 
increased expression of PAI-1 within the LA.39 Elevated levels 
of PAI-1 may inhibit fibrinolytic activity, thereby promoting 
thrombus formation. Furthermore, NO has a role in the inhi-
bition of platelet activation and recruitment.40 Histological 
examination of the atria also revealed that AF was associated 
with overexpression of tissue factor and vWf in conjunction 
with endothelial injury.41 The resultant effects on endothelial 
dysfunction from both AF and its comorbidities may promote a 
prothrombotic state.
Abnormal blood flow (eg, blood stasis)
Blood stasis is the final component of Virchow’s triad that 
occurs as a direct result of AF and contributes to thrombus 
formation (table 3). Reduced blood flow within the atria may 
be seen on echocardiography as an echogenic, smoke- like, 
swirl (known as ‘spontaneous echo contrast’). The incidence 
of this phenomenon is significantly increased in the presence 
of AF,42 which causes sluggish flow to occur as a result of dila-
tation, increased fibrosis and loss of atrial systole. Use of MRI 
has demonstrated that AF results in reduced mean and peak 
LA velocities, and increased LA stasis.43 Furthermore, these 
adverse effects extended to include the LAA and were more 
pronounced in patients with AF during their scan. There was 
also a graded, negative influence of the CHA2DS2- VASc score 
on these parameters.43
Effects of reduced blood flow
There are several mechanisms by which reduced blood flow 
may contribute to thrombus formation. Spontaneous echo 
contrast detected on trans- oesophageal echocardiogram in 
patients with AF was independently associated with increased 
haematocrit, fibrinogen concentration and LA dimension.44 
These changes may promote thrombus formation through 
erythrocyte aggregation and by providing fuel to the coagu-
lation cascade.
Abnormal blood stasis in AF may also lead to a prothrom-
botic state by its effects on vWf. Under normal physiological 
conditions, vWf is rapidly degraded by ADAM metallopep-
tidase with thrombospondin type 1 motif 13 (ADAMTS13) 
into an inactive form. However, the actions of ADAMTS13 is 
flow- dependent45 and hence reduced blood flow in AF may 
disrupt this regulatory process. It has been demonstrated 
that AF is associated with higher levels of vWf antigen and 
activity, and that there is a direct relationship between the 
degree of LA stasis and elevated vWf.46 Furthermore, these 
biomarkers were associated with the presence and intensity 
of spontaneous echo contrast on trans- oesophageal echo-
cardiography, and were independent predictors of LAA 
thrombus.46
In addition, reduced blood flow within the LA in patients 
with AF has been directly linked to P- selectin levels.47 
However, this effect was only evident for patients with severe 
blood stasis, as graded by spontaneous contrast echo.
Thromboembolism in atrial fibrillation
A prothrombotic state increases the risk of thrombus forma-
tion, thereby occlusion of blood vessels, and localised isch-
aemia or infarction. In addition to local thrombus formation, 
blood flow may also be affected by thrombus dislodgement 
from a distant site (‘thromboembolism’). There are various 
sources from where this thrombus may originate. Although 
the presence of AF predisposes to thrombus formation in both 
the arterial and venous circulatory systems, it has tradition-
ally been linked to complications predominantly within the 
arterial system. This is supported by a recent study demon-
strating that while AF was independently associated with an 
increased risk of pulmonary embolism, the long- term risk of 
ischaemic stroke was more pronounced (HR 2.45 vs 1.72).48 
Reasons for this are not fully understood but may relate to 
possible intrinsic differences between the LA compared with 
the right atrium such as a reduced ability to activate protein 
C and lower expression of thrombomodulin,49 both of which 
have anticoagulant properties. Furthermore, AF appears to be 
associated with cardiac chamber- specific responses in terms of 
platelet activation and aggregation,50 and endothelial dysfunc-
tion.39 The effects of AF on venous thromboembolism, and 
the temporal relationship between AF and thrombogenesis are 
discussed in the online supplementary.
ConClusIon
The mechanisms contributing to a prothrombotic state in 
AF fulfils Virchow’s triad of hypercoagulability, endothelial 
injury and abnormal blood stasis. Improved understanding of 
the various factors involved in thrombus formation will allow 
better clinical risk stratification and targeted therapies in AF. 
There remains much to be understood in this area.
Take home messages
 ► Atrial fibrillation (AF) and its associated comorbidities result 
in a prothrombotic state.
 ► Thrombogenesis in AF is linked to Virchow’s triad of 
hypercoagulability, vessel wall abnormalities and blood stasis.
 ► Central changes of hypercoagulability precedes those in the 
peripheral system.
 ► Vessel wall abnormalities in AF are related to atrial fibrosis 
and endothelial dysfunction.
 ► Blood stasis occurs secondary to cardiac dilatation, increased 
fibrosis and loss of atrial systole.
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